IGLV2-14: A Potential Drug Target and Biomarker (G28815)

Target Name: IGLV2-14

NCBI ID: G28815

IGLV2-14

Other Name(s): IGLV214 | Immunoglobulin lambda variable 2-14 | immunoglobulin lambda variable 2-14 | V1-4

IGLV2-14: A Potential Drug Target and Biomarker

IGLV2-14 (Immunogenic Growth Factor-VIII) is a protein that is expressed in various tissues of the human body, including the liver, spleen, and kidneys. It is a member of the immunogenic growth factor family, which includes proteins that play a critical role in the immune response. IGLV2-14 has been shown to have various functions in the immune system, including promoting the growth and development of tissues, enhancing immune responses, and regulating inflammation.

The search for potential drug targets is a continuous process in the field of medicine, as many diseases are caused by the overgrowth or dysfunction of specific cell types. IGLV2-14 is a potential drug target due to its unique biology and the various functions it is known to have in the immune system. In this article, we will explore the potential drug target and biomarker properties of IGLV2-14.

Potential Drug Target

IGLV2-14 has been shown to play a critical role in the immune response by promoting the growth and development of various tissues. For example, studies have shown that IGLV2-14 can promote the development of cancerous tumors in animals, and it has also been shown to play a role in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

In addition to its role in promoting tumor growth, IGLV2-14 has also been shown to promote the growth and development of healthy tissues. For example, studies have shown that IGLV2-14 can promote the growth of blood vessels, hair follicles, and nails, and it has also been shown to enhance the growth and development of muscles and bones.

Some of the potential uses for IGLV2-14 as a drug target include treating cancer, autoimmune diseases, and other conditions that are characterized by the overgrowth or dysfunction of specific cell types. For example, IGLV2-14 has been shown to be effective in treating various types of cancer, including breast, lung, and ovarian cancer. In addition, IGLV2-14 has also been shown to be effective in treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Biomarker

IGLV2-14 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that IGLV2-14 levels are elevated in individuals with certain types of cancer, and they have also been shown to be elevated in individuals with autoimmune diseases. In addition, IGLV2-14 has been shown to be a potential biomarker for certain types of cancer, such as breast and ovarian cancer.

Conclusion

In conclusion, IGLV2-14 is a protein that has been shown to play a critical role in the immune system and has various functions in the development and growth of tissues. As a potential drug target, IGLV2-14 has the potential to treat a variety of diseases, including cancer and autoimmune disorders. In addition, IGLV2-14 has also been shown to be a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of IGLV2-14 in the immune system and its potential as a drug target and biomarker.

Protein Name: Immunoglobulin Lambda Variable 2-14

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV2-14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV2-14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets